This study presents a promising approach for predicting AD risk and progression using widely accessible, noninvasive sMRI‐derived biomarkers, with a particular emphasis on amyloid and tau pathologies—previously established core biomarkers for early AD risk prediction (Blennow et al. 2010; Jack et al. 2010). The gene discussed is MAPT; the disease is Alzheimer disease.